Andrew D. Dick|James T. Rosenbaum|Hassan Al-Dhibi|Rubens Belfort|Antoine P. Brézin|Soon Phaik Chee|Janet L. Davis|Athimalaipet V Ramanan|Koh-Hei Sonoda|Ester Carreño|Heloísa Nascimento|S. Ben Salah|Sherveen Salek|Jay Siak|Laura R Steeples|Massimo Accorinti|Nisha R. Acharya|Alfredo Adán|Rupesh Agrawal|Nurullah Akkoç|Saeed Al Ghamdi|Turki Al Ghamdi|Ahmed Saati|Nasser Alsabaani|Mohamed Al-Shamarani|Artur Bachta|Talin Barisani?Asenbauer|Nicholas A. V. Beare|Fernanda Belga Ottoni Porto|R. Blanco|Anita Chan Sook Yee|Vinod Chandran|Christophe Chiquet|Hiok Hee Chng|Andrius Cimbalas|Luca Cimino|Miguel Cordero?Coma|Carmen Cristóbal|Miguel Cuevas|João Eurico Fonseca|Joke de Boer|Alejandra de la Torre|Ilse De Schryver|Larissa Derzko-Dzulynsky|David Díaz?Valle|Claudia Eugenia Duran Merino|Andrea Facskó|Luís Figueira|Alejandro Fonollosa|Éric Fortin|Richard Gale|Mauro Gargiulo|Sandra García|José María García Ruiz de Morales|Nataša Gašperši?|Debra A. Goldstein|Marta Guedes|Yan Guex?Crosier|Ahmet Gül|Rola N. Hamam|Muhammad Haroon|Kenichi Hasegawa|Arnd Heiligenhaus|Claire Hooper|Yih?Shiou Hwang|De?Kuang Hwang|Xavier Juanola|Toshikatsu Kaburaki|Sibel Kaday?fç?lar|John H. Kempen|Takeshi Kezuka|Amin Kherani|Maarja Kirsimäe|Kaisu Kotaniemi|Aleksandra Kraut|Agnieszka Kubicka?Trz?ska|Lucia Kuffová|Susan Lightman|Lyndell L Lim|Wei?Wen Lim|Peter McCluskey|Mark A. McGuire|Pierfrancesco Mirabelli|Elisabetta Miserocchi|Marta Misiuk?Hoj?o|Cristina Muccioli|Santiago León Atehortúa Muñoz|Conor C Murphy|Philip I. Murray|Zoltán Zsolt Nagy|Kenichi Namba|Piergiorgio Neri|Quan Dong Nguyen|Donncha O’Gradaigh|Mohammed A. Omair|Kati Otsa|Y?lmaz Özyazgan|Flora de Pablo|Maria Pia Paroli|Uwe Pleyer
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
University of Bristol|University College London|National Institute for Health Research|Moorfields Eye Hospital|Legacy Health|Oregon Health & Science University|King Khaled Eye Specialist Hospital|Universidade Federal de São Paulo|Instituto da Visão|Hôpital Cochin|Université Paris Cité|Singapore National Eye Center|National University of Singapore|Singapore Eye Research Institute|University of Miami|University of Bristol|University Hospitals Bristol NHS Foundation Trust|Kyushu University|University Hospitals Bristol NHS Foundation Trust|Bristol Eye Hospital|Universidade Federal de São Paulo|Hôpital Cochin|Université Paris Cité|Oregon Health & Science University|Johns Hopkins Medicine|Johns Hopkins University|Singapore National Eye Center|National University of Singapore|Singapore Eye Research Institute|Manchester Royal Eye Hospital|University of Manchester|University Hospitals Bristol NHS Foundation Trust|Bristol Eye Hospital
topican international expertled consensus initiative develop systematic evidencebased recommendations treatment noninfectious uveitis era biologicsclinical relevancethe availability biologic agents treatment human eye disease altered practice patterns management noninfectious uveitis current guidelines insufficient assure optimal use noncorticosteroid systemic immunomodulatory agentsmethodsan international expert steering committee comprising 9 uveitis specialists including ophthalmologists rheumatologists identified clinical questions together 6 bibliographic fellows trained uveitis conducted preferred reporting items systematic reviews metaanalyses protocol systematic review literature english language studies january 1996 june 2016 medline ovid central cochrane library embase cinahl scopus biosis web science publications included randomized controlled trials prospective retrospective studies sufficient followup case series 15 cases peerreviewed articles handsearched conference abstracts key conferences proposed statements circulated among 130 international uveitis experts review total 44 globally representative group members met late 2016 refine guidelines using modified delphi technique assigned oxford levels evidenceresultsin total 10 questions addressed resulting 21 evidencebased guidance statements covering following topics start noncorticosteroid immunomodulatory therapy including biologic nonbiologic agents data collect treatment modify withdraw treatment select agents based individual efficacy safety profiles evidence specific uveitic conditions shared decisionmaking communication among providers safety monitoring also addressed part recommendations pharmacoeconomic considerations addressedconclusionsconsensus guidelines developed based published literature expert opinion practical experience bridge gap clinical needs medical evidence support treatment patients noninfectious uveitis noncorticosteroid immunomodulatory agents international expertled consensus initiative develop systematic evidencebased recommendations treatment noninfectious uveitis era biologics availability biologic agents treatment human eye disease altered practice patterns management noninfectious uveitis current guidelines insufficient assure optimal use noncorticosteroid systemic immunomodulatory agents international expert steering committee comprising 9 uveitis specialists including ophthalmologists rheumatologists identified clinical questions together 6 bibliographic fellows trained uveitis conducted preferred reporting items systematic reviews metaanalyses protocol systematic review literature english language studies january 1996 june 2016 medline ovid central cochrane library embase cinahl scopus biosis web science publications included randomized controlled trials prospective retrospective studies sufficient followup case series 15 cases peerreviewed articles handsearched conference abstracts key conferences proposed statements circulated among 130 international uveitis experts review total 44 globally representative group members met late 2016 refine guidelines using modified delphi technique assigned oxford levels evidence total 10 questions addressed resulting 21 evidencebased guidance statements covering following topics start noncorticosteroid immunomodulatory therapy including biologic nonbiologic agents data collect treatment modify withdraw treatment select agents based individual efficacy safety profiles evidence specific uveitic conditions shared decisionmaking communication among providers safety monitoring also addressed part recommendations pharmacoeconomic considerations addressed consensus guidelines developed based published literature expert opinion practical experience bridge gap clinical needs medical evidence support treatment patients noninfectious uveitis noncorticosteroid immunomodulatory agents